Rienso (ferumoxytol) withdrawn

on the 16 March 2015

Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY
Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY

The intravenous iron preparation Rienso (ferumoxytol) has been withdrawn for commercial reasons. Launched in 2012, it was licensed for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

More from MIMS

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

Trimbow (beclometasone/formoterol/glycopyrronium) can...